Brief: Clinuvel Pharmaceuticals Says Scenesse Validated And Accepted For Review
23/12/2024 01:28
Dec 23 (Reuters) - Clinuvel Pharmaceuticals Ltd
CUV.AX :
* SCENESSE VALIDATED AND ACCEPTED FOR REVIEW AHEAD OF HEALTH
CANADA'S TARGET VALIDATION WINDOW
Source text: ID:nASX2qHFy4
Further company coverage: CUV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist